Ba/F3 cells transformed by the TPM3-JAK2 fusion were sensitive to a JAK kinase inhibitor, documenting the potential application of JAK2 kinase inhibitors for the treatment of T-ALL cases with JAK2 fusion genes. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.